About Ibex Biosciences
Ibex Biosciences is a private company based in Rockville, Maryland. It has reported $5,235,000 raised in four offerings on Form D since January 2020. Its chief executive is Michael Karlin.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Feb 5, 2025 | Feb 20, 2025 | $70,000of $12.5M target | 3 | $23,333 | Equity, DebtRule 506(c) | Form D ↗ |
| Jul 5, 2021 | Jul 15, 2021 | $1,000,000of $5.0M target | 2 | $500K | EquityRule 504 | Form D ↗ |
| Sep 25, 2018 | Jan 2, 2020 | $2,400,000fully sold | 15 | $160K | EquityRule 504 | Form D ↗ |
| Aug 15, 2017 | Jan 2, 2020 | $1,765,000of $2.4M target | 6 | $294K | EquityRule 504 | Form D ↗ |
| Total, four offerings | $5,235,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Ibex Biosciences's Form D filed Feb 20, 2025.
RF
Roy Feinson
Director
AC
Alberto Croci
Executive officer and director
MK
Michael Karlin
Co-Chief Executive Officer and director
SK
Sylvan Karlin
Director